• 8027 Citations
  • 37 h-Index
1987 …2024
If you made any changes in Pure these will be visible here soon.

Research Outputs 1987 2019

Filter
Article

α-interferon 2a and 13-cis-retinoic acid for the treatment of metastatic renal cell carcinoma

Wong, M., Goldstein, D., Woo, H., Testa, G. & Gurney, H., 2002, In : Internal Medicine Journal. 32, 4, p. 158-162 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Isotretinoin
NSC 153174
Renal Cell Carcinoma
Interferon-alpha
Tretinoin

Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025

Escudier, B., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F., Gurney, H., Sosman, J. A., Zalewski, P. G., Harmenberg, U., McDermott, D. F., Choueiri, T. K., Richardet, M., Tomita, Y., Ravaud, A., Doan, J., Zhao, H., Hardy, H. & George, S., Sep 2017, In : European Urology. 72, 3, p. 368-376 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Therapeutics
Karnofsky Performance Status
Response Evaluation Criteria in Solid Tumors
nivolumab

The use of L-dopa and carbidopa in metastatic malignant melanoma

Gurney, H., Coates, A. & Kefford, R., Jan 1991, In : Journal of Investigative Dermatology. 96, 1, p. 85-87 3 p.

Research output: Contribution to journalArticleResearchpeer-review

Carbidopa
Levodopa
Melanoma
Maximum Tolerated Dose
Toxicity

The prevalence and correlates of supportive care needs in testicular cancer survivors: A cross-sectional study

Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G. C., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., Alam, M., Cox, K. & Olver, I., Nov 2013, In : Psycho-Oncology. 22, 11, p. 2557-2564 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Testicular Neoplasms
Survivors
Cross-Sectional Studies
Psychology
Survival Rate

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study

Smith, A. B., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G. C., Stockler, M. R., Hovey, E., Stubbs, J., Turner, S., Hruby, G., Gurney, H., Alam, M., Cox, K. & King, M. T., 1 Apr 2016, In : Journal of Cancer Survivorship. 10, 2, p. 223-233 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Testicular Neoplasms
Survival Rate
Quality of Life
Psychology
Survivors

The management of primary fallopian tube carcinoma

Gurney, H., Murphy, D. & Crowther, D., 1990, In : British Journal of Obstetrics and Gynaecology. 97, 9, p. 822-826 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Fallopian Tubes
Carcinoma
Drug Therapy
Radiotherapy
Recurrence

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

Roncolato, F. T., Chatfield, M., Houghton, B., Toner, G., Stockler, M., Thomson, D., Friedlander, M., Gurney, H., Rosenthal, M., Grimison, P. & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP), 1 Aug 2016, In : Internal Medicine Journal. 46, 8, p. 893-898 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Germ Cell and Embryonal Neoplasms
Bleomycin
Lung
Vital Capacity
Lung Volume Measurements

Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?

Lee, C. I., Fox, P., Balakrishnar, B., Balleine, R. L., Gao, B., Provan, P., Coulter, S., Liddle, C., Hui, R., Wong, M., Gurney, H. & Wilcken, N., 1 Aug 2019, In : Breast. 46, p. 52-57 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Hot Flashes
Tamoxifen
Cytochrome P-450 CYP2D6
4-hydroxy-N-desmethyltamoxifen
Compliance

Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

Lee, C. I. & Gurney, H., 1 Nov 2016, In : Cancer Forum. 40, 3, p. 4-10 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Cytochrome P-450 CYP2D6
Tamoxifen
Hormones
Breast Neoplasms
Selective Estrogen Receptor Modulators

Tactic: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Ferraro, D., Goldstein, D., O’Connell, R. L., Zalcberg, J. R., Sjoquist, K. M., Tebbutt, N. C., Grimison, P., McLachlan, S., Lipton, L. L., Vasey, P., Gebski, V. J., Aiken, C., Cronk, M., Ng, S., Karapetis, C. S., Shannon, J., Shannon, J., Tebbutt, N., Ng, S., Cronk, M. & 48 othersKarapetis, C., Sjoquist, K., Aiken, C., Do, V., Marschner, I., Friedlander, M., Gurney, H., Simes, J., Hague, W., O’Connell, R., Gebski, V., Aiken, C., Gorzeman, M., Pike, R., Miranda, K., Waring, P., Ferraro, D., Lau, D., Fox, S., Tebbutt, N., Liu, Y., Vasey, P., Wood, T., Cronk, M., Cocks, C., Simmons, K., Shannon, J., McCourt, J., Jefford, M., Hobinchet, A., Grimison, P., Mirco, B., Sagong, J., Ng, S., Dudukovic, S., Aghmesheh, M., Parker, S., Segelov, E., Ratnayake, L., McLachlan, S., Ranieri, N., Varma, S., Page, J., Heyer, E., Abdi, E., Chorlton, C., Lipton, L. & Wilkinson, L., 1 Aug 2016, In : Cancer Chemotherapy and Pharmacology. 78, 2, p. 361-367 7 p.

Research output: Contribution to journalArticleResearchpeer-review

gemcitabine
Biliary Tract Neoplasms
Cisplatin
Toxicity
Labels

Skull metastases masquerading as cerebral secondaries in patients with cancer

Wright, J., Gurney, H. & Glare, P., 1998, In : Australian and New Zealand Journal of Medicine. 28, 1, p. 62 1 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy

Gurney, H., Kefford, R. & Stuart-Harris, R., 29 Jul 1989, In : The Lancet. 334, 8657, p. 241-244 4 p.

Research output: Contribution to journalArticleResearchpeer-review

pamidronate
Phosphates
Kidney
Calcium
Hypercalcemia

Recurrent transitional cell carcinoma of the renal pelvis presenting as diabetes insipidus

Gurney, H. P. & Page, J., 1989, In : European Journal of Surgical Oncology. 15, 3, p. 282-284 3 p.

Research output: Contribution to journalArticleResearchpeer-review

Deamino Arginine Vasopressin
Diabetes Insipidus
Kidney Pelvis
Transitional Cell Carcinoma
Pituitary Gland

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Crumbaker, M., Guminski, A., Gurney, H., Sabanathan, D., Wong, S. & Pavlakis, N., Apr 2018, In : Asia-Pacific Journal of Clinical Oncology. 14, 2, p. e45-e49 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Appointments and Schedules
Therapeutics
sunitinib
Survival

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Nam, K., Frenkl, T. L., Perini, R. F., De Wit, R. & Bajorin, D. F., 1 Jun 2019, In : Annals of Oncology. 30, 6, p. 970-976 7 p., mdz127.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
docetaxel
Paclitaxel
Drug Therapy
Neoplasms
Platinum
Plasma (human)
Metabolites
Mass spectrometry
Mass Spectrometry
Pharmaceutical Preparations

Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer

Won, A. C. M., Gurney, H., Marx, G., De Souza, P. & Patel, M. I., Aug 2013, In : BJU international. 112, 4, p. E250-E255 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostate
Prostatic Neoplasms
Prostatectomy
Radiotherapy
Therapeutics

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer

Wong, M., Balleine, R. L., Blair, E. Y. L., McLachlan, A. J., Ackland, S. P., Garg, M. B., Evans, S., Farlow, D., Collins, M., Rivory, L. P., Hoskins, J. M., Mann, G. J., Clarke, C. L. & Gurney, H., 1 Jun 2006, In : Journal of Clinical Oncology. 24, 16, p. 2448-2455 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Pharmacokinetics
Neoplasms
Cytochrome P-450 CYP3A
Neutrophils
Body Surface Area

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: The ClearSun study

Kloth, J. S. L., Klümpen, H. J., Yu, H., Eechoute, K., Samer, C. F., Kam, B. L. R., Huitema, A. D. R., Daali, Y., Zwinderman, A. H., Balakrishnar, B., Bennink, R. J., Wong, M., Schellens, J. H. M., Mathijssen, R. H. J. & Gurney, H., Mar 2014, In : Clinical Pharmacokinetics. 53, 3, p. 261-269 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Cytochrome P-450 CYP3A
Pharmacokinetics
Midazolam
Phenotype
Nonlinear Dynamics

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S. & Sorich, M. J., 26 Sep 2017, In : British Journal of Cancer. 117, 7, p. 913-920 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Biomarkers
Therapeutics
Leukocyte Count
Research
C-Reactive Protein

Positive lifestyle changes following urological cancer diagnoses: an Australian interview based study

Cerimagic, S., Ahmadi, N., Gurney, H., Hossack, T. & Patel, M. I., 1 Jun 2015, In : International Journal of Human Rights in Healthcare. 8, 2, p. 110-119 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Urologic Neoplasms
Life Style
cancer
Interviews
interview

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

Nath, C. E., Shaw, P. J., Trotman, J., Zeng, L., Duffull, S. B., Hegarty, G., McLachlan, A. J., Gurney, H., Kerridge, I., Kwan, Y. L., Presgrave, P., Tiley, C., Joshua, D. & Earl, J., May 2010, In : British Journal of Clinical Pharmacology. 69, 5, p. 484-497 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Melphalan
Multiple Myeloma
Pharmacokinetics
Population
Area Under Curve

Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

Motzer, R. J., Rakhit, A., Thompson, J., Gurney, H., Selby, P., Figlin, R., Negrier, S., Ernst, S., Siebels, M., Ginsberg, M., Rittweger, K. & Hooftman, L., 1 Nov 2002, In : Annals of Oncology. 13, 11, p. 1799-1805 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Interferons
Asthenia
Subcutaneous Injections
Transaminases

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

Lin, H-M., Mahon, K. L., Spielman, C., Gurney, H., Mallesara, G., Stockler, M. R., Bastick, P., Briscoe, K., Marx, G., Swarbrick, A. & Horvath, L. G., 11 Apr 2017, In : British Journal of Cancer. 116, 8, p. 1002-1011 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Castration
MicroRNAs
docetaxel
Prostatic Neoplasms
Biomarkers

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Poehlein, C. H., Perini, R. F. & Bajorin, D. F., 16 Mar 2017, In : New England Journal of Medicine. 376, 11, p. 1015-1026 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Confidence Intervals
Carcinoma
Drug Therapy
Platinum
Neoplasms

Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011

van Leeuwen, M. T., Gurney, H., Turner, J. J., Turner, S. L., Pearson, S. A., Laaksonen, M. A., Harnett, P., Balakrishnar, B., Sabanathan, D. & Vajdic, C. M., 1 Aug 2016, In : Cancer Epidemiology. 43, p. 15-21 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Germ Cell and Embryonal Neoplasms
Pediatrics
Incidence
Neoplasms
Germinoma

Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia

Gurney, H., Grill, V. & Martin, T. J., 26 Jun 1993, In : The Lancet. 341, 8861, p. 1611-1613 3 p.

Research output: Contribution to journalArticleResearchpeer-review

pamidronate
Parathyroid Hormone-Related Protein
Hypercalcemia
Neoplasms
Albumins

Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation

Nguyen, V., Gurney, H. & Van Der Poorten, D., 10 Jan 2011, In : Journal of Clinical Oncology. 29, 2, p. 1-3 3 p.

Research output: Contribution to journalArticleResearchpeer-review

Paclitaxel as first-line treatment for metastatic breast cancer

Bishop, J. F., Dewar, J., Toner, G. C., Tattersall, M. H., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J. & Stephenson, J., 1997, In : ONCOLOGY. 11, 4 SUPPL. 3, p. 19-23 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Paclitaxel
Breast Neoplasms
Therapeutics
Quality of Life
Cyclophosphamide

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Powles, T., Motzer, R. J., Escudier, B., Pal, S., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., Gross-Goupil, M., Grande, E., Suarez, C., Markby, D. W., Arroyo, A., Dean, M., Choueiri, T. K. & George, D., 11 Sep 2018, In : British Journal of Cancer. 119, 6, p. 663-669 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Renal Cell Carcinoma
Disease-Free Survival
Survival
Therapeutics
Everolimus

Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand

Bell, D., Grimes, D., Gurney, H., Dalley, D., Blackwell, T., Fox, R. & Jeffery, M., Oct 2008, In : Internal Medicine Journal. 38, 10, p. 751-757 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Epoetin Alfa
New Zealand
Drug Therapy
Reticulocytes
Erythropoietin

Nivolumab versus everolimus in advanced renal-cell carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A. & 8 othersKollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L. A., Waxman, I. M., Sharma, P. & CheckMate 025 Investigators, 5 Nov 2015, In : New England Journal of Medicine. 373, 19, p. 1803-1813 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Confidence Intervals
Survival
Everolimus
nivolumab

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B. & 19 othersMelichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M. O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S., Tannir, N. M. & CheckMate 214 Investigators, 1 Oct 2019, In : The Lancet Oncology. 20, 10, p. 1370-1385 16 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Safety
Therapeutics
Disease-Free Survival
Advisory Committees

Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S. & 13 othersBarrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., Escudier, B. & CheckMate 214 Investigators, 5 Apr 2018, In : New England Journal of Medicine. 378, 14, p. 1277-1290 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Disease-Free Survival
Survival
nivolumab
ipilimumab

Nivolumab in the treatment of advanced renal cell carcinoma

Arasaratnam, M. & Gurney, H., Jul 2018, In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Neoplasms
Interleukin-2
Therapeutics
Biomarkers

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

Mahon, K. L., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R. J., Chatfield, M. D., Boyer, M. J., Stockler, M. R., Marx, G., Gurney, H., Mallesara, G., Molloy, P. L., Horvath, L. G. & Clark, S. J., 28 Oct 2014, In : British Journal of Cancer. 111, 9, p. 1802-1809 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Glutathione Transferase
Genetic Markers
Epigenomics
Prostatic Neoplasms
Drug Therapy

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study

Colomba, E., Le Teuff, G., Eisen, T., Stewart, G. D., Fife, K., Larkin, J., Biondo, A., Pickering, L., Srinivasan, A., Boyle, H., Derosa, L., Sternberg, C. N., Recine, F., Ralph, C., Saldana, C., Barthélémy, P., Bernhard, J. C., Gurney, H., Verhoest, G., Vauleon, E. & 11 othersBigot, P., Berger, J., Pfister, C., Gravis, G., Rodier, J-M., Culine, S., Caty, A., Rolland, F., Priou, F., Escudier, B. & Albiges, L., 1 Jul 2017, In : European Journal of Cancer. 80, p. 55-62 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Sirolimus
Renal Cell Carcinoma
Treatment Failure
Kidney
Confidence Intervals

Maintaining bone health in patients with prostate cancer

Holmes-Walker, J., Woo, H., Gurney, H., Do, V. T. & Chipps, D. R., 20 Feb 2006, In : Medical Journal of Australia. 184, 4, p. 176-179 4 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Bone and Bones
Androgens
Health
Bone Density

Long-term follow-up of patients treated with intermittent hormone therapy for advanced prostate cancer

Hruby, G., Gurney, H., Turner, S., Berry, M., Harnett, P. & Gebski, V., May 1999, In : Prostate Journal. 1, 3, p. 138-143 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Hormones
Therapeutics
Goserelin
Androgen Antagonists

Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Arasaratnam, M., Crumbaker, M., Bhatnagar, A., McKay, M. J., Molloy, M. P. & Gurney, H., Jul 2019, In : Cancer Chemotherapy and Pharmacology. 84, 1, p. 139-146 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Pharmacokinetics
Prostatic Neoplasms
Pharmaceutical Preparations
Chemotherapy
Drug Therapy

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H. N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J., Stephenson, J. & Canetta, R., Aug 1999, In : Journal of Clinical Oncology. 17, 8, p. 2355-2364 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Paclitaxel
Combination Drug Therapy
Breast Neoplasms
Therapeutics
Infection
Inflammatory Breast Neoplasms
Epirubicin
Ifosfamide
Vincristine
Radiotherapy

Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor

Gurney, H., Anderson, H., Radford, J., Potter, M. R., Swindell, R., Steward, W., Kamthan, A., Chang, J., Weiner, J., Thatcher, N. & Crowther, D., 1992, In : European Journal of Cancer. 28, 1, p. 105-112 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Small Cell Lung Carcinoma
Granulocyte-Macrophage Colony-Stimulating Factor
Drug Therapy
Infection
Neutropenia

Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: An effect of improved systemic therapy?

Lin, C., Turner, S., Gurney, H. & Peduto, A., Aug 2008, In : Journal of Medical Imaging and Radiation Oncology. 52, 4, p. 376-381 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Hormones
Neoplasm Metastasis
Therapeutics
Natural History

Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem?

Chang, D. K., Merrett, N. D., Biankin, A. V. & NSW Pancreatic Cancer Network, Jul 2008, In : Journal of Gastroenterology and Hepatology (Australia). 23, 7 Pt 1, p. 1036-45 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Pancreatic Neoplasms
Pancreatectomy
Mortality
Group Psychotherapy
Survival

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H. & Donskov, F., 2013, In : Journal of Translational Medicine. 11, p. 189 1 p.

Research output: Contribution to journalArticleResearchpeer-review

Chemotherapy
Neutropenia
Non-Small Cell Lung Carcinoma
Ovarian Neoplasms
Neutrophils

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype

Gurney, H., Wong, M., Balleine, R. L., Rivory, L. P., McLachlan, A. J., Hoskins, J. M., Wilcken, N., Clarke, C. L., Mann, G. J., Collins, M., Delforce, S. E., Lynch, K. & Schran, H., 14 Jul 2007, In : Clinical Pharmacology and Therapeutics. 82, 1, p. 33-40 8 p.

Research output: Contribution to journalArticleResearchpeer-review

P-Glycoprotein
Genotype
Cytochrome P-450 CYP3A
Gastrointestinal Stromal Tumors
Homozygote

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Gurney, H., de Campos, E. S., Dodwell, D., Kamthan, A. & Thatcher, N., 1991, In : European Journal of Cancer and Clinical Oncology. 27, 5, p. 565-567 3 p.

Research output: Contribution to journalArticleResearchpeer-review

Ifosfamide
Mitomycin
Non-Small Cell Lung Carcinoma
Karnofsky Performance Status
Therapeutics

Hypercalcaemia in small cell lung cancer: Report of a case associated with parathyroid hormone-related protein (PTHrP)

Stuart-Harris, R., Ahern, V., Danks, J. A., Gurney, H. & Martin, T. J., 1993, In : European Journal of Cancer. 29, 11, p. 1601-1604 4 p.

Research output: Contribution to journalArticleResearchpeer-review

Parathyroid Hormone-Related Protein
Small Cell Lung Carcinoma
Hypercalcemia
Parathyroid Hormone Receptor Type 1
Neoplasms

How to calculate the dose of chemotherapy

Gurney, H., 22 Apr 2002, In : British Journal of Cancer. 86, 8, p. 1297-1302 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Body Surface Area
Drug Therapy
Pharmaceutical Preparations
Guidelines
Testicular Neoplasms